346 related articles for article (PubMed ID: 12692539)
21. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
Lyakhovich A; Surralles J
Cancer Lett; 2006 Jan; 232(1):99-106. PubMed ID: 16246487
[TBL] [Abstract][Full Text] [Related]
22. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
Fei P; Yin J; Wang W
Cell Cycle; 2005 Jan; 4(1):80-6. PubMed ID: 15611632
[TBL] [Abstract][Full Text] [Related]
23. Fancf-deficient mice are prone to develop ovarian tumours.
Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H
J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857
[TBL] [Abstract][Full Text] [Related]
24. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
25. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
26. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.
Meyer S; White DJ; Will AM; Eden T; Sim A; Brown R; Strathdee G
Br J Haematol; 2006 Jul; 134(1):61-3. PubMed ID: 16803569
[TBL] [Abstract][Full Text] [Related]
27. X-linked inheritance of Fanconi anemia complementation group B.
Meetei AR; Levitus M; Xue Y; Medhurst AL; Zwaan M; Ling C; Rooimans MA; Bier P; Hoatlin M; Pals G; de Winter JP; Wang W; Joenje H
Nat Genet; 2004 Nov; 36(11):1219-24. PubMed ID: 15502827
[TBL] [Abstract][Full Text] [Related]
28. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2.
Hussain S; Wilson JB; Blom E; Thompson LH; Sung P; Gordon SM; Kupfer GM; Joenje H; Mathew CG; Jones NJ
DNA Repair (Amst); 2006 May; 5(5):629-40. PubMed ID: 16621732
[TBL] [Abstract][Full Text] [Related]
29. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
30. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
[TBL] [Abstract][Full Text] [Related]
31. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
32. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
33. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
34. Genetic subtyping of Fanconi anemia by comprehensive mutation screening.
Ameziane N; Errami A; Léveillé F; Fontaine C; de Vries Y; van Spaendonk RM; de Winter JP; Pals G; Joenje H
Hum Mutat; 2008 Jan; 29(1):159-66. PubMed ID: 17924555
[TBL] [Abstract][Full Text] [Related]
35. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
[TBL] [Abstract][Full Text] [Related]
36. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Wreesmann VB; Estilo C; Eisele DW; Singh B; Wang SJ
ORL J Otorhinolaryngol Relat Spec; 2007; 69(4):218-25. PubMed ID: 17409780
[TBL] [Abstract][Full Text] [Related]
38. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
39. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
40. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
